Improved overall survival after contralateral risk‐reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis. Issue 3 (8th July 2014)

• Record Type: Journal Article
• Authors: A.M. Heemskerk‐Gerritsen, Bernadette; Rookus, Matti A.; Aalfs, Cora M.; Ausems, Margreet G.E.M.; Collée, Johanna M.; Jansen, Liesbeth; Kets, C. Marleen; Keymeulen, Kristien B.M.I.; Koppert, Linetta B.; Meijers‐Heijboer, Hanne E.J.; Mooij, Thea M.; Tollenaar, Rob A.E.M.; Vasen, Hans F.A.; HEBON; Hooning, Maartje J.; Seynaeve, Caroline
• Is Part Of: International journal of cancer. Volume 136:Issue 3(2015:Feb. 01)
• Page Start: 668
• Page End: 677
• Publication Date: 2014-07-08
• Subjects: Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.29032
• Languages: English
• ISSNs: 0020-7136

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Data on survival of BRCA1/2‐associated primary breast cancer (PBC) patients who opt for subsequent contralateral risk‐reducing mastectomy (CRRM) are scarce and inconsistent. We examined the efficacy of CRRM on overall survival in mutation carriers with a history of PBC. From a Dutch multicentre cohort, we selected 583 BRCA‐associated PBC patients, being diagnosed between 1980 and 2011. Over time, 242 patients (42%) underwent CRRM and 341 patients (58%) remained under surveillance. Survival analyses were performed using Cox models, with CRRM as a time‐dependent covariate. The median follow‐up after PBC diagnosis was 11.4 years. In the CRRM group, four patients developed contralateral breast cancer (2%), against 64 patients (19%) in the surveillance group (<italic>p</italic> < 0.001). The mortality was lower in the CRRM group than in the surveillance group (9.6 and 21.6 per 1000 person‐years of observation, respectively; adjusted hazard ratio 0.49, 95% confidence interval 0.29–0.82). Survival benefit was especially seen in young PBC patients (<40 years), in patients having a PBC with differentiation grade 1/2 and/or no triple‐negative phenotype, and in patients not treated with adjuvant chemotherapy. We conclude that CRRM is associated with improved overall survival in BRCA1/2 mutation carriers with a history of PBC. Further research is warranted to develop a model based on age at diagnosis and tumour and treatment characteristics that can predict survival benefit for specific subgroups of patients, aiming at further personalized counselling and improved decision making.</p> </abstract>